Is CE a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Celanese Corporation (CE) rests on Deleveraging through cash and asset sales: Every capital-allocation lever Celanese has pulled since late 2024 points the same direction: a ~95% dividend cut, a paused repurchase program, reduced capital spending at roughly ~$128M in the first half of 2026, and the ~$493M Micromax sale to Element Solutions that closed in February. The bear case rests on leverage dominates the risk list. Analysts covering it publish targets from $52.00 to $86.00 against a $48.96 share price on November 16, 2026, so even the professionals disagree by 54% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
CE key stats
At $48.96 on November 16, 2026, Celanese Corporation (CE) has a market cap of $5.4B, a P/E of 19.8 on trailing earnings (7.9 on forward earnings) and a dividend yield of 0.25%.
- Market cap
- $5.4B
- P/E (trailing)
- 19.8
- P/E (forward)
- 7.9
- EPS (trailing 12 months)
- $2.47
- Price to book
- 1.3
- Dividend yield
- 0.25%
- Beta
- 0.71
Market cap, P/E and yield are measured at the $48.96 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Celanese Corporation (CE)?
The last two weeks for Celanese Corporation, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- CE closed at $48.96 on November 16, 2026, up 0.4% over the past five trading days (from $48.75).
- On November 16, 2026, Celanese Corporation filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
- On November 3, 2026, Celanese Corporation filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 9, 2026, Keybanc raised its target to $59.00 from $57.00 (Overweight).
- On November 5, 2026, Wells Fargo lowered its target to $60.00 from $65.00 (Overweight).
- On November 4, 2026, Citigroup raised its target to $65.00 from $58.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Celanese Corporation makes chemicals in two very different businesses. Its Acetyl Chain segment produces acetic acid, vinyl acetate monomer, acetate tow and related derivatives, largely commodity molecules sold on price and cost position, and it generated about ~$2.4B of net sales in the first half of 2026. Engineered Materials, the larger half at roughly ~$2.8B of first-half sales, sells specialty polymers, nylon, elastomers and compounds into automotive, medical, electronics and industrial applications where formulations are specified into a customer's part. Around ~11,400 employees run the plant network, which spans North America, Europe and Asia, with a large equity-affiliate presence in China. Investors are really underwriting a capital structure. Celanese borrowed roughly ~$11B to buy DuPont's Mobility and Materials business in 2022, then walked straight into a multi-year downturn in automotive builds and European industrial demand, so total debt sits near ~$12.4B against about ~$1.4B of cash and only ~$4.6B of book equity. Goodwill write-downs in Engineered Materials, which now total ~$2.7B of accumulated impairment, drove the trailing twelve-month net loss of roughly ~$1.16B even though 2026 has been profitable so far: second-quarter revenue rose ~8.7% to ~$2.75B, net income was ~$125M, and adjusted EPS of $2.45 beat the ~$2.22 estimate after the first quarter had missed. Management cut the quarterly dividend by about 95% starting in early 2025, paused buybacks, sold the Micromax business for ~$493M, and amended financial ratio maintenance covenants on its U.S. credit facilities in both 2025 and on July 31, 2026. Compliance held as of June 30, 2026, and the auditor has raised no going-concern doubt, but the equity trades at about half of trailing sales (and about 7.8x forward earnings) because the outcome sits on a narrower ledge than a chemical company's revenue line implies. As of October 16, 2026 the shares closed at $47.11, up ~12% year to date and ~18% over one year but well below a 52-week high of ~$70.70. Third-quarter results are scheduled for November 2, 2026, with consensus near $1.56 of EPS on ~$2.62B of revenue.
The bull case: what would have to be true for $86.00
The most optimistic published target on CE is $86.00, +75.7% from the $48.96 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Deleveraging through cash and asset sales
Every capital-allocation lever Celanese has pulled since late 2024 points the same direction: a ~95% dividend cut, a paused repurchase program, reduced capital spending at roughly ~$128M in the first half of 2026, and the ~$493M Micromax sale to Element Solutions that closed in February. Management has said further opportunistic dispositions and monetizations of product lines are on the table. Each dollar of debt retired accrues disproportionately to a ~$5.2B equity stub sitting under ~$11.0B of net debt, which is the arithmetic that makes the deleveraging story the whole story. Trailing free cash flow has improved to roughly ~$950M, which is the pool those repayments come from.
2. Acetyl Chain pricing and regional supply dislocation
Acetyl Chain net sales rose ~19% year over year in the second quarter of 2026, driven almost entirely by price rather than volume, as regional supply outages tightened acetic acid and derivative markets. Celanese has historically argued its integrated, low-cost acetyl position lets it earn through the bottom of the cycle and capture outsized spread when supply tightens. That quarter lifted total revenue ~8.7% and produced a $2.45 EPS beat, while consensus for the third quarter (~$1.56) implies some of the spread fades. Commodity pricing of this kind reverses as quickly as it arrives, so the durability of the second-quarter step-up is one of the more consequential open questions in the model.
3. Cost reduction and footprint rationalization
Closure of the Lanaken, Belgium facility during the second half of 2026 sits alongside broader company-wide optimization projects, with about ~$60M of additional exit and shutdown costs expected through 2027 and restructuring liabilities of roughly ~$55M carried at mid-year. European operating costs, energy in particular, have been a persistent drag on the Engineered Materials margin structure. Shrinking that footprint lowers the volume threshold at which the segment converts demand into cash, which matters more than usual when covenant headroom is the constraint.
4. Automotive and industrial demand recovery
Engineered Materials volumes fell about ~3% in the first half of 2026 on soft automotive builds in Europe and North America and continued destocking in industrial channels. Content per vehicle in electrified platforms has historically been a tailwind for engineered polymers, since battery housings, connectors and thermal management parts use more specialty resin than their predecessors. A genuine volume recovery would show up in the operating leverage of a plant network currently running below its design throughput.
The bear case: what would have to be true for $52.00
The most pessimistic published target is $52.00, +6.2% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Celanese Corporation is worth if the risks below bite instead of the drivers above.
Leverage dominates the risk list. Total debt of roughly ~$12.4B against about ~$4.6B of book equity leaves a debt-to-equity ratio near ~2.7 and an enterprise value of roughly ~$16.2B against a ~$5.2B market cap, so a modest change in enterprise value swings the equity hard in either direction. Celanese amended financial ratio maintenance covenants in its U.S. credit facilities during 2025 and again on July 31, 2026, and while it was in compliance as of June 30, 2026 and expects to remain so, its own filing notes that results materially below expectation could require seeking a further amendment or waiver. On the legal side, follow-on damages claims arising from the company's July 2020 settlement of a European Commission ethylene-purchasing competition investigation remain live: ~14 claims have been filed since 2023 by parties including Shell, Repsol entities, BASF, Dow, ExxonMobil, BP, MOL Group and Braskem in the District Court of Amsterdam and the German courts of Munich and Dortmund, and on July 30, 2026 the Amsterdam court dismissed the Shell and Repsol claims in their entirety as not plausible, a ruling subject to appeal. Celanese states it cannot estimate the potential impact of the remaining matters. Several plaintiff law firms announced investigations of potential securities claims after the November 2024 earnings and guidance disappointment, though no filed securities class action appears in the company's Legal Proceedings disclosure, and the auditors have raised no going-concern doubt.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CE already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CE
18 analysts cover CE, with an average target of $63.00 (+28.7% against $48.96) and a split of 10 buy, 8 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CE forecast and price target page.
How is CE valued?
Market cap, P/E and dividend yield at today's price are in the CE key stats above. The business figures below come from Celanese Corporation's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$9.7B; Q2 2026 ~$2.75B, up ~8.7% YoY
- Q2 2026 adjusted EPS: $2.45 vs ~$2.22 estimate
- Net income (TTM): ~-$1.16B, driven by goodwill and asset impairments
- Margins (TTM): ~21% gross, ~11% operating
- Net debt: ~$11.0B (total debt ~$12.4B less cash ~$1.4B)
As of October 2026: Two very different valuations sit on the same company. Equity holders pay roughly half of trailing sales and under 8x forward earnings, which looks cheap until the ~$11.0B of net debt is added and the whole enterprise prices at about ~1.7x sales and ~9.9x EBITDA, a fairly ordinary multiple for a chemical producer in a soft cycle. Free cash flow of roughly ~$950M over the trailing twelve months is what services the debt, and analysts' mean target near $61 sits well above the October 16, 2026 close of $47.11, a gap that mostly prices how much of that cash reaches the equity.
How do you decide if CE is a buy?
Whether CE is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CE indirectly through an index or sector ETF before adding more.
What would change your mind on CE
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Deleveraging through cash and asset sales stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: leverage dominates the risk list fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CE against your real portfolio and see your actual exposure before deciding.
Your questions about Celanese Corporation
Ask Walnut's AI anything about CE and see how it fits what you own.
FAQ
Is CE a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Deleveraging through cash and asset sales, with revenue (ttm) at ~$9.7B; Q2 2026 ~$2.75B, up ~8.7% YoY. The bear case rests on leverage dominates the risk list. Analysts covering it are spread from $52.00 to $86.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CE?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Leverage dominates the risk list. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $52.00, +6.2% from the $48.96 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for CE?
+
Deleveraging through cash and asset sales. Every capital-allocation lever Celanese has pulled since late 2024 points the same direction: a ~95% dividend cut, a paused repurchase program, reduced capital spending at roughly ~$128M in the first half of 2026, and the ~$493M Micromax sale to Element Solutions that closed in February. The most optimistic analyst target on CE is $86.00, +75.7% from the $48.96 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CE?
+
Leverage dominates the risk list. Total debt of roughly ~$12.4B against about ~$4.6B of book equity leaves a debt-to-equity ratio near ~2.7 and an enterprise value of roughly ~$16.2B against a ~$5.2B market cap, so a modest change in enterprise value swings the equity hard in either direction. Celanese amended financial ratio maintenance covenants in its U.S. credit facilities during 2025 and again on July 31, 2026, and while it was in compliance as of June 30, 2026 and expects to remain so, its own filing notes that results materially below expectation could require seeking a further amendment or waiver. On the legal side, follow-on damages claims arising from the company's July 2020 settlement of a European Commission ethylene-purchasing competition investigation remain live: ~14 claims have been filed since 2023 by parties including Shell, Repsol entities, BASF, Dow, ExxonMobil, BP, MOL Group and Braskem in the District Court of Amsterdam and the German courts of Munich and Dortmund, and on July 30, 2026 the Amsterdam court dismissed the Shell and Repsol claims in their entirety as not plausible, a ruling subject to appeal. Celanese states it cannot estimate the potential impact of the remaining matters. Several plaintiff law firms announced investigations of potential securities claims after the November 2024 earnings and guidance disappointment, though no filed securities class action appears in the company's Legal Proceedings disclosure, and the auditors have raised no going-concern doubt. The most pessimistic published target is $52.00, +6.2% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Celanese Corporation do?
+
Celanese makes chemicals in two very different businesses, engineered polymers sold into autos and electronics, and commodity acetyls.
What would have to change for CE to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Deleveraging through cash and asset sales) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (leverage dominates the risk list) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Celanese actually make?
+
Two segments split the business. Acetyl Chain produces acetic acid, vinyl acetate monomer, acetate tow and derivatives sold as intermediates into paints, adhesives, textiles and filters. Engineered Materials sells specialty polymers, nylon, elastomers and compounds designed into automotive parts, medical devices, electronics and industrial equipment, and it was the larger half at roughly ~$2.8B of first-half 2026 sales.
Why is the market cap so much smaller than revenue?
+
Debt absorbs most of the enterprise. Celanese carries about ~$12.4B of total debt against roughly ~$1.4B of cash, so an enterprise value near ~$16.2B leaves only about ~$5.2B for shareholders as of October 2026. Revenue of ~$9.7B belongs to the whole capital structure, not to the equity, which is why price to sales of ~0.5x and enterprise value to sales of ~1.7x tell such different stories about the same company.
How did Celanese end up this levered?
+
Financing the 2022 purchase of DuPont's Mobility and Materials business, at roughly ~$11B, added the bulk of the borrowings. Automotive and European industrial demand then weakened for several consecutive years, so the acquired earnings arrived well below the level assumed at the time. Goodwill impairments in Engineered Materials now total ~$2.7B of accumulated write-downs, which is the accounting record of that gap.
Walnut is informational, not investment advice, and gives no verdict on CE. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.